Comparison of attitudes toward long-acting injectable antipsychotics among psychiatrists and patients

International Clinical Psychopharmacology

Volumn 28, Issue 2, 2013, Pages 80-86

  Kim, Sung Wan ^a   Lee, Yo Han ^b   Jang, Ji Eun ^a   Yoo, Taeyoung ^a   Kim, Jae Min ^a   Shin, Il Seon ^a   Yoon, Jin Sang ^a  

^a Chonnam National University Medical School   (South Korea)

^b St John Hospital   (South Korea)

Author keywords

adherence; antipsychotics; long acting injection; psychiatrist; schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; DOCTOR PATIENT RELATION; DRUG USE; FEMALE; HEALTH SURVEY; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT SATISFACTION; PRIORITY JOURNAL; PSYCHIATRIST; SOCIAL ASPECT;

ADULT; ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; ATTITUDE TO HEALTH; CROSS-SECTIONAL STUDIES; DELAYED-ACTION PREPARATIONS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HEALTH CARE SURVEYS; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; INTERNET; MALE; NEUROPSYCHIATRY; PATIENT EDUCATION AS TOPIC; PATIENT SATISFACTION; PHYSICIAN'S PRACTICE PATTERNS; PSYCHOTIC DISORDERS; REPUBLIC OF KOREA; SCHIZOPHRENIA;

EID: 84873408260     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32835d30ae     Document Type: Article

References (22)

1. Adams CE, Fenton MK, Quraishi S, David AS (2001). Systematic meta-review of depot antipsychotics for people with schizophrenia. Br J Psychiatry 179: 290-299.
2. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Press Inc.
3. Chen EY, Hui CL, Lam MM, Chiu CP, Law CW, Chung DW, et al. (2010). Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ 341:c4024.
4. Emsley R, Oosthuizen PP, Koen L, Niehaus DJ, Martinez G (2012). Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study. J Clin Psychiatry 73:e541-e547.
5. Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL, et al. (2001). Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 158:1835-1842.
6. Heres S, Hamann J, Kissling W, Leucht S (2006). Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 67:1948-1953.
7. Heres S, Schmitz FS, Leucht S, Pajonk FG (2007). The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol 22: 275-282.
8. Heres S, Hamann J, Mendel R, Wickelmaier F, Pajonk FG, Leucht S, et al. (2008). Identifying the profile of optimal candidates for antipsychotic depot therapy: a cluster analysis. Prog Neuropsychopharmacol Biol Psychiatry 32: 1987-1993.
9. Jaeger M, Rossler W (2010). Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res 175:58-62.
10. Kane JM (2011). Improving treatment adherence in patients with schizophrenia. J Clin Psychiatry 72:e28.
11. Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW, et al. (1998). Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. In: Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW, et al., editors. Eur Neuropsychopharmacol 8: 55-66.
12. Kang G, Kang SH, Yoon HJ, Lee JI (2010). Attitudes of patients with schizophrenia and their caretakers toward treatment with long-acting injectable antipsychotic medication. J Korean Assoc Soc Psychiatry 15:67-73.
13. Kim SW, Yoon JS, Choi SK (2006). Survey of medication adherence in patients with schizophrenia-Korean ADHES data. Hum Psychopharmacol Clin Exp 21:533-537.
14. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S (2011). Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 127:83-92.
15. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. (2012). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379:2063-2071.
16. Nasrallah HA (2007). The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 115:260-267.
17. Razali MS, Yahya H (1995). Compliance with treatment in schizophrenia: a drug intervention program in a developing country. Acta Psychiatr Scand 91: 331-335.
18. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. (1999). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56:241-247.
19. Sim K, Su A, Ungvari GS, Fujii S, Yang SY, Chong MY, et al. (2004). Depot antipsychotic use in schizophrenia: an East Asian perspective. Hum Psychopharmacol 19:103-109.
20. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P (2011). A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168:603-609.
21. Walburn J, Gray R, Gournay K, Quraishi S, David AS (2001). Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 179:300-307.
22. Weiden PJ, Olfson M (1995). Cost of relapse in schizophrenia. Schizophr Bull 21:419-429.